| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$76.1M | ROE | −25.30% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecules for patients with genetically defined diseases of high unmet medical need in the United States. Its clinical-stage candidate is pociredir, a fetal hemoglobin inducer in phase 1b trials for sickle cell disease and beta-thalassemia. The company also discovers programs for diamond-blackfan anemia, bone marrow failure syndromes, and fibrotic disorders, and has a license agreement with CAMP4.
| Market Cap | $247.9M | Trading Days | 1763 |
| 52W High | 15.74 |
| 52W Low | 2.83 |
| % Off High | −76.37% |
| YTD | −67.11% | 1Y | −52.37% |
| 3Y | −3.38% | 5Y | −51.69% |
| Since incept. (ann.) | −16.76% |
| Ann. Volatility (1Y) | 99.84% | Ann. Volatility (3Y) | 95.19% |
| Sharpe (1Y) | −0.21 | Sharpe (3Y) | 0.55 |
| Max Drawdown (1Y) | −78.49% | Max Drawdown (3Y) | −79.08% |
| Beta (3Y, vs SPY) | 2.59 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| MREO | Mereo BioPharma Group plc | $246.9M | — |
| MGNX | MACROGENICS INC | $244.7M | — |
| SIGA | SIGA TECHNOLOGIES INC | $239.6M | 10.4 |
| TRDA | Entrada Therapeutics, Inc. | $236.0M | — |
| ELDN | Eledon Pharmaceuticals, Inc. | $262.4M | — |
| NRXP | NRX Pharmaceuticals, Inc. | $232.8M | — |
| TTRX | Turn Therapeutics Inc. | $231.8M | — |
| CYDY | CytoDyn Inc. | $266.4M | — |
| QTTB | Q32 Bio Inc. | $266.4M | 6.5 |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $267.8M | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $273.0M | — |
| RNAC | Cartesian Therapeutics, Inc. | $224.8M | — |
